Horber D H, von Ballmoos P, Schott H, Schwendener R A
Department of Internal Medicine, Medical Oncology, University Hospital, Zürich, Switzerland.
Br J Cancer. 1995 Nov;72(5):1067-73. doi: 10.1038/bjc.1995.466.
The clonogenic growth inhibition, the cell cycle dependence of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) cytotoxicity and the capability to induce apoptosis in ara-C-sensitive and -resistant HL-60 cells were investigated and compared with arabinofuranosylcytosine (ara-C). In the clonogenic assay with sensitive HL-60 cells, ara-C was slightly more effective than a liposomal preparation of NHAC, whereas in the resistant cells, NHAC revealed its potency to overcome ara-C resistance, resulting in a 23-fold lower 50% inhibitory concentration compared with ara-C. Cell cycle dependent cytotoxicity and induction of apoptosis were studied by flow cytometry, using the bromodeoxyuridine-propidium iodide and terminal transferase method respectively. In contrast to ara-C, NHAC exerted no phase-specific toxicity at low concentrations (< 40 microM). At higher concentrations the S-phase-specific toxicity increased, probably resulting from ara-C formed from NHAC. NHAC induced apoptosis at higher drug concentrations than ara-C, however apoptosis appeared not to be limited to the S-phase cells. Apoptosis occurred in both cell lines within 2-4 h after drug exposure. These results give further evidence that NHAC exerts its cytotoxicity by different mechanisms of action than ara-C and might therefore be active in ara-C-resistant tumours.
研究了N4-十六烷基-1-β-D-阿拉伯呋喃糖基胞嘧啶(NHAC)对ara-C敏感和耐药的HL-60细胞的克隆形成生长抑制、细胞周期依赖性细胞毒性以及诱导凋亡的能力,并与阿糖胞苷(ara-C)进行了比较。在对敏感HL-60细胞的克隆形成试验中,ara-C比NHAC的脂质体制剂稍有效,而在耐药细胞中,NHAC显示出克服ara-C耐药性的能力,其50%抑制浓度比ara-C低23倍。分别使用溴脱氧尿苷-碘化丙啶和末端转移酶方法,通过流式细胞术研究了细胞周期依赖性细胞毒性和凋亡诱导。与ara-C不同,NHAC在低浓度(<40μM)时没有阶段特异性毒性。在较高浓度下,S期特异性毒性增加,可能是由于NHAC形成了ara-C。NHAC比ara-C在更高的药物浓度下诱导凋亡,然而凋亡似乎不限于S期细胞。药物暴露后2-4小时内,两种细胞系均发生凋亡。这些结果进一步证明,NHAC通过与ara-C不同的作用机制发挥其细胞毒性,因此可能对ara-C耐药肿瘤有活性。